Amgen’s Horizon Therapeutics Merger Headed to September Trial

The US Federal Trade Commission’s antitrust suit to block Amgen Inc.’s $27.8 billion takeover of Horizon Therapeutics Plc is heading to trial in September.

In a filing late Tuesday, lawyers for Amgen, Horizon and the FTC agreed to a two-week hearing starting on Sept. 11. US District Judge John Knessmust approve the proposal, but at a status conference last week the judge said he could issue a decision by Oct. 24, or four weeks after the September hearing.

The FTC sued over the proposed acquisition earlier this month, arguing it would allow Amgen to entrench Horizon’s monopoly on ...